Bladder cancer is a histologically and clinically heterogenous disease. Most bladder
cancers are urothelial carcinomas, which frequently develop distinct histological subtypes …

Identifying the histologic subtypes and divergent differentiation in bladder cancer is
important to establish the correct diagnosis and classification and may also be clinically …

Cisplatin-based chemotherapy remains the primary treatment for unresectable and
metastatic muscle-invasive bladder cancers (MIBCs). However, tumors frequently develop …

Small cell/neuroendocrine bladder cancers (SCBCs) are rare and highly aggressive tumors
that are associated with poor clinical outcomes. We discovered that lineage-specific …

Muscle-invasive bladder cancer (MIBC) is associated with limited response rates to systemic
therapy leading to a significant risk of recurrence and death. A recently discovered histone …

Simple Summary Bladder cancer is a heterogeneous disease that is composed of epithelia
with varying transcriptional, mutational and lineage signatures. The epithelia of bladder …

Small cell carcinomas (SMC) of the lung are now molecularly classified based on the
expression of transcriptional regulators (NEUROD1, ASCL1, POU2F3, and YAP1) and …

Background Neoadjuvant chemotherapy (neoCTX) has been recommended as the optimal
strategy in surgically resectable neuroendocrine carcinoma (NEC) of the urinary tract (NEC …

Small cell cervical carcinoma (SCCC) is the most common neuroendocrine tumor in the
female genital tract, with an unfavorable prognosis and lacking an evidence‐based …

Bladder cancer is a heterogeneous disease, which exhibits a wide spectrum of clinical and
pathologic features. Recent genomic studies have revealed that distinct molecular …